NCT06693960 Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach
| NCT ID | NCT06693960 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Washington State University |
| Condition | Interaction |
| Study Type | INTERVENTIONAL |
| Enrollment | 16 participants |
| Start Date | 2024-09-26 |
| Primary Completion | 2026-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 16 participants in total. It began in 2024-09-26 with a primary completion date of 2026-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this clinical trial is to determine how the supplement oregano affects how the body metabolizes pharmaceutical drugs.
Eligibility Criteria
Inclusion Criteria: * Between 18-64 years old and healthy * Not taking any medications (prescription and non-prescription) or dietary/herbal supplements that can interfere with study drug pharmacokinetics * Willing to abstain from consuming dietary/herbal supplements and citrus juices for several weeks * Willing to abstain from cannabis/marijuana, hemp, and THC- and CBD-containing products for several weeks * Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and the morning of the first day of each study arm * Willing to abstain from consuming any alcoholic beverages for at least 1 day prior to any study day and during the study day * Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms). Specifically, regardless of the use hormonal-based birth control, a non-hormonal method should be used for the duration of the study and for three weeks following cessation of participation. * Willing to abstain from consuming oregano (as a food additive or otherwise) for the duration of the study * Geographically located within a 40-mile radius of Spokane and have the time to participate Exclusion Criteria: * Under 18 or over 64 years old * Taking medications or dietary/herbal supplements that can interfere with study drug pharmacokinetics * Have a major illness * Taking medication/supplements for a mineral deficiency * History of intolerance or allergy to oregano or any of the cocktail drugs (caffeine, dextromethorphan, losartan, midazolam, and omeprazole) * Use of cannabis/marijuana, hemp, and CBD- and/or THC-containing products within the last month * Currently using drugs or illicit substances for recreational purposes * Pregnant or nursing * Geographically located outside the 40-mile radius of Spokane and do not have the time to participate * Cannot read and speak English
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06693960 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Interaction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06693960 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06693960 currently recruiting?
Yes, NCT06693960 is actively recruiting participants. Contact the research team at mary.paine@wsu.edu for enrollment information.
Where is the NCT06693960 trial being conducted?
This trial is being conducted at Spokane, United States.
Who is sponsoring the NCT06693960 clinical trial?
NCT06693960 is sponsored by Washington State University. The trial plans to enroll 16 participants.